LeMaitre Vascular, Inc. LMAT R2K
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Excellent profit margin of 24.3%.
- Compounding revenue at 15.6% over 5 years.
- Profit CAGR of 40.9% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LMAT LeMaitre Vascular, Inc. R2K | 94.65 | 34.80 | $2.16B | 1.06% | 13.87% | 16.55% | 15.58% | 40.91% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 24.14M | 25.75M | 24.82M | - | 25.99M | 27.02M | 24.16M | - | 28.48M | 29.48M | 29.10M | - | 30.55M | 24.85M | 36.42M | - | 35.88M | 40.67M | 38.37M | - | 39.56M | 39.03M | 39.03M | - | 47.08M | 50.12M | 47.41M | - | 53.48M | 55.85M | - | - | 59.87M | 64.23M | 61.05M | 64.45M | 66.55M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.45M | 19.26M | 15.09M | 18.26M | 18.16M |
| Gross Profit | 15.37M | 17.02M | 16.19M | 17.35M | 17.52M | 17.58M | 18.25M | 18.47M | 18.99M | 17.25M | 19.22M | 19.46M | 20.32M | 20.17M | 19.91M | 20.48M | 17.03M | 22.70M | 24.40M | 23.80M | 26.76M | 24.87M | 25.96M | 25.96M | 27.81M | 25.07M | 26.05M | 30.88M | 32.09M | 30.82M | 33.27M | 36.66M | 38.47M | - | - | 41.42M | 44.97M | 45.95M | 46.19M | 48.40M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.79M | 28.83M | 25.64M | 27.36M | 30.62M |
| Operating Income | 3.78M | 5.34M | 3.91M | 4.19M | 5.54M | 5.05M | 6.32M | 4.86M | 11.54M | 4.61M | 7.19M | 4.43M | 5.92M | 5.91M | 4.93M | 4.35M | 4.87M | 10.02M | 9.54M | 7.95M | 11.11M | 9.07M | 8.30M | 7.93M | 5.78M | 6.15M | 6.97M | 7.87M | 9.45M | 9.18M | 10.21M | 11.87M | 14.38M | - | - | 12.63M | 16.14M | 20.31M | 18.83M | 17.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.08M | 22.02M | 26.48M | 24.20M | 23.59M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.29M | 1.30M | 1.30M | 1.30M | 1.30M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.24M | 18.07M | 22.57M | 20.30M | 19.67M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.23M | 4.29M | 5.21M | 4.72M | 3.99M |
| Net Income | 2.60M | 3.23M | 2.60M | 3.22M | 4.63M | 5.04M | 4.28M | 3.85M | 8.75M | 4.31M | 6.03M | 3.51M | 4.62M | 5.18M | 4.61M | 3.17M | 3.50M | 7.51M | 7.03M | 5.93M | 8.30M | 6.50M | 6.17M | 6.04M | 3.52M | 5.46M | 5.63M | 6.04M | 8.10M | 7.50M | 8.46M | 9.89M | 11.83M | - | - | 11.01M | 13.78M | 17.36M | 15.58M | 15.68M |
| Diluted EPS | 0.14 | 0.17 | 0.13 | 0.16 | 0.23 | 0.25 | 0.21 | 0.19 | 0.43 | 0.21 | 0.30 | 0.17 | 0.23 | 0.25 | 0.23 | 0.16 | 0.17 | 0.37 | 0.34 | 0.28 | 0.40 | 0.30 | 0.28 | 0.27 | 0.16 | 0.25 | 0.25 | 0.27 | 0.36 | 0.33 | 0.38 | 0.44 | 0.52 | - | - | 0.48 | 0.60 | 0.75 | 0.68 | 0.68 |
| R&D Expense | 1.63M | 1.54M | - | 1.66M | 1.63M | 1.76M | - | 1.82M | 1.99M | 2.04M | - | 2.24M | 2.26M | 2.28M | - | 2.99M | 2.14M | 2.10M | - | 2.84M | 2.65M | 2.85M | - | 2.93M | 3.35M | 3.46M | - | 3.88M | 4.52M | 4.22M | - | 4.09M | 4.28M | 3.66M | - | 4.09M | 3.54M | 2.97M | - | 4.06M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 100.87M | 105.57M | 117.23M | 129.37M | - | 161.65M | 193.48M | 219.86M | 249.60M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.76M | 66.44M | 68.96M | 71.06M |
| Gross Profit | 37.30M | 41.72M | 40.23M | 40.87M | 45.12M | 48.43M | 54.17M | 62.94M | 70.70M | 73.94M | 79.85M | 84.62M | - | 104.90M | 127.05M | 150.90M | 178.54M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.96M | 89.85M | 98.64M | 110.63M |
| Operating Income | 1.95M | 4.01M | 3.69M | 4.24M | 4.52M | 6.34M | 11.51M | 16.34M | 21.10M | 28.21M | 21.18M | 28.79M | - | 29.94M | 37.20M | 52.26M | 67.91M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 36.92M | 48.99M | 66.69M | 90.79M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 205.00K | 5.18M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 27.49M | 39.48M | 56.88M | 75.18M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.85M | 9.37M | 12.84M | 17.45M |
| Net Income | 1.60M | 6.01M | 2.14M | 2.57M | 3.20M | 3.92M | 7.76M | 10.59M | 17.18M | 22.94M | 17.93M | 21.22M | - | 20.64M | 30.11M | 44.04M | 57.73M |
| Diluted EPS | 0.10 | 0.37 | 0.13 | 0.16 | 0.20 | 0.23 | 0.42 | 0.55 | 0.86 | 1.13 | 0.88 | 1.04 | - | 0.93 | 1.34 | 1.93 | 2.52 |
| R&D Expense | 5.91M | 5.49M | 4.42M | 5.09M | 5.24M | 4.67M | 5.48M | 6.14M | 6.64M | 8.20M | 9.28M | 10.10M | 11.80M | 13.29M | 16.97M | 15.65M | 14.14M |
Compounded Sales Growth
| 5 Years: | 15.58% |
| 1 Year: | 11.20% |
Compounded Profit Growth
| 5 Years: | 40.91% |
| 1 Year: | 41.70% |
Stock Price Performance
| 1 Year: | +16.20% |
| 6 Months: | +13.91% |
| 3 Months: | -12.09% |
| 1 Month: | -11.55% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 63.27M | 59.69M | 63.06M | 70.49M | 81.49M | 90.70M | 101.92M | 126.32M | 153.09M | 188.34M | 252.81M | - | 310.48M | 346.78M | 551.82M | 615.69M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 161.73M | 194.60M | 402.19M | 468.23M |
| Cash & Equivalents | 15.89M | 23.19M | 22.61M | 20.13M | 16.45M | 14.71M | 18.69M | 27.45M | 24.29M | 19.10M | 26.32M | 11.79M | 26.76M | - | 19.13M | 24.27M | 25.61M | 28.24M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.28M | 52.33M | 55.94M | 58.25M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.04M | 25.06M | 30.06M | 33.61M |
| Total Liabilities | - | - | 10.92M | 7.60M | 10.17M | 13.93M | 13.29M | 12.82M | 14.42M | 16.55M | 22.85M | 40.20M | 80.24M | - | 42.27M | 48.88M | 214.53M | 222.17M |
| Current Liabilities | - | - | 10.39M | 6.54M | 8.39M | 10.22M | 10.04M | 10.37M | 10.48M | 13.19M | 19.76M | 20.85M | 25.14M | - | 25.33M | 29.88M | 30.61M | 36.32M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 167.77M | 168.65M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.60M | 19.09M | 185.69M | 185.59M |
| Total Equity | 45.75M | 48.21M | 52.36M | 52.09M | 52.89M | 56.56M | 68.21M | 77.88M | 87.50M | 109.77M | 130.24M | 148.14M | 172.57M | - | 268.20M | 297.90M | 337.29M | 393.52M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.66M | 23.91M | 24.15M | 24.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.44M | 7.05M | 3.17M | 4.72M | 5.39M | - | - | 16.90M | 22.87M | 19.51M | 14.18M | 34.80M | - | 25.38M | 36.75M | 44.12M | 81.25M |
| Investing Cash Flow | 2.18M | -5.24M | -1.82M | -5.20M | -6.19M | - | - | -17.21M | -28.96M | -7.05M | -24.10M | -52.89M | - | -10.37M | -24.71M | -200.12M | -64.94M |
| Financing Cash Flow | -376.00K | -2.33M | -3.80M | -3.16M | -961.00K | - | - | -2.58M | 80.00K | -4.42M | -4.62M | 32.16M | - | -9.23M | -7.13M | 158.10M | -14.54M |
| Capital Expenditure | -577.00K | -2.47M | -2.02M | -1.21M | -2.73M | -1.17M | -2.27M | -2.84M | - | - | - | - | - | -3.23M | -7.26M | -6.96M | -6.78M |
| Free Cash Flow | 4.86M | 4.58M | 1.15M | 3.51M | 2.65M | - | - | 14.05M | - | - | - | - | - | 22.15M | 29.49M | 37.16M | 74.47M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.77M | 4.91M | 2.11M | 1.77M |
| Share Buybacks | 686.00K | 2.52M | 2.21M | 2.02M | 373.00K | 211.00K | 266.00K | 311.00K | 778.00K | 741.00K | 683.00K | 570.00K | 802.00K | 642.00K | 853.00K | 1.72M | 1.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 70.1% | 70.0% | 68.1% | 65.4% | - | 64.9% | 65.7% | 68.6% | 71.5% |
| Operating Margin % | - | - | - | - | - | - | - | - | 20.9% | 26.7% | 18.1% | 22.3% | - | 18.5% | 19.2% | 23.8% | 27.2% |
| Net Margin % | - | - | - | - | - | - | - | - | 17.0% | 21.7% | 15.3% | 16.4% | - | 12.8% | 15.6% | 20.0% | 23.1% |
| ROE % | 3.3% | 11.5% | 4.1% | 4.9% | 5.7% | 5.7% | 10.0% | 12.1% | 15.6% | 17.6% | 12.1% | 12.3% | - | 7.7% | 10.1% | 13.1% | 14.7% |
| ROCE % | - | 7.6% | 6.9% | 7.8% | 7.5% | 8.9% | 14.3% | 17.9% | 18.7% | 21.2% | 12.6% | 12.6% | - | 10.5% | 11.7% | 10.0% | 11.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 13.76% | 3.14M | $297.59M |
| 2 | Conestoga Capital Advisors, LLC | 6.46% | 1.48M | $139.78M |
| 3 | First Trust Advisors LP | 4.37% | 998.07K | $94.47M |
| 4 | Vanguard Capital Management LLC | 3.99% | 912.06K | $86.33M |
| 5 | Copeland Capital Management, LLC | 3.81% | 870.69K | $82.41M |
| 6 | State Street Corporation | 3.75% | 855.78K | $81.00M |
| 7 | Congress Asset Management Co | 3.65% | 834.53K | $78.99M |
| 8 | Geneva Capital Management LLC | 3.30% | 753.99K | $71.37M |
| 9 | Geode Capital Management, LLC | 2.88% | 658.45K | $62.32M |
| 10 | Vanguard Portfolio Management LLC | 2.46% | 562.77K | $53.27M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LMAT